Alert: New Earnings Report (11/2/23)-BioCryst Pharmaceuticals Inc (NASDAQ: BCRX).


BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has reported a loss for its third fiscal quarter (ending September 30) of $-0.19 versus a loss $-0.23 for the same period a year ago. This result was in line with the consensus estimate of $-0.19. For the latest four quarters through September 30, E.P.S. were $-1.25 versus $-1.05 for the same period a year ago.


Recent Price Action

BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock declined by -1.6% on 11/2/23. The shares closed at $5.64. The stock has been weak relative to the market over the last nine months but has risen 3.1% during the last week.

Current PriceTarget Research Rating

With future capital returns forecasted to be below the cost of capital, BCRX is expected to be a major Value Eraser.

BioCryst Pharmaceuticals is currently unrated.

Rating Review

The stock is currently unrated.

Be the first to comment

Leave a Reply

Your email address will not be published.